Ośrodek Badań Klinicznych "METABOLICA" lek. Robert Witek

Verified siteinfo

Poland Ul. Najswietszej Marii Panny 9b, 33-100 Tarnow, Poland

4 trials recruiting
Obesity · Type 2 diabetes mellitus · Cardiac failure
Adult patients

About Specializations

Ośrodek Badań Klinicznych "METABOLICA" lek. Robert Witek in Tarnow, Poland specialises in clinical trials of conditions such as Obesity, Type 2 diabetes mellitus, Cardiac failure, Hypertension, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of gastroenterology research, focusing on innovative treatments for ulcerative colitis. The ongoing studies aim to enhance patient outcomes through advanced therapeutic strategies.

Ulcerative Colitis
Endoscopic Improvement
Symptomatic Remission

By exploring the efficacy and safety of novel compounds, the center contributes significantly to the understanding and management of chronic gastrointestinal conditions.

Cardiology

Specializing in cardiology, the center is dedicated to advancing treatment options for chronic heart failure. Research efforts are concentrated on reducing cardiovascular risks and improving patient quality of life.

Heart Failure with Reduced Ejection Fraction
Cardiovascular Risk Reduction
Heart Failure Hospitalization

The center's work in this field is pivotal in developing therapies that address the complex needs of heart failure patients, aiming for long-term health improvements.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Najswietszej Marii Panny 9b33-100 TarnowPoland

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 10
Partner status: Verified site

More sites in Tarnow Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

18 clinical trials

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting

Registered drug

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational

Poland

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S